Evidence map›Paper›PMID 41109697›Full record

ReviewClinics in liver disease2025

Novel Therapeutics for Hepatocellular Carcinoma.

Mohamed I Elsaid, Ashish Manne

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in liver disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mohamed I ElsaidDivision of Biostatistics and Population Health, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA; Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Cancer Control, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Electronic address: mohamed.elsaid@osumc.edu.
Ashish ManneDivision of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Soledad A Fernandez · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

Recent advances have transformed the therapeutic landscape for advanced hepatocellular carcinoma (HCC). Immunotherapy combinations, such as atezolizumab-bevacizumab, ipilimumab-nivolumab, and STRIDE, have raised survival expectations, while novel checkpoints (LAG-3, TIGIT, TIM-3) and targeted therapies addressing FGFR4 and β-catenin are entering late-phase trials. Additionally, metabolic and stress-pathway inhibitors targeting ferroptosis, GLS1, NRF2, and YAP-TAZ show promising synergy with existing treatments. Precision oncology innovations, including liquid biopsy and AI-driven imaging, further enhance patient-tailored approaches. Addressing equity and global implementation barriers will ensure these advances benefit all patients, marking a decisive shift toward personalized and equitable HCC care.

Indexed as

Carcinoma, HepatocellularImmunotherapyLiver NeoplasmsHumansImmune Checkpoint InhibitorsMolecular Targeted TherapyImmune Checkpoint InhibitorsFerroptosis inductionFGFR4 inhibitionImmunotherapyLiquid biopsyNext-generation checkpoint inhibitorsPrecision oncologyβ-catenin modulation

Identifiers

PMID41109697
PMCPMC13555504

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.